Fessem, M.A. van

patient tamoxifen cancer allele plasma study genotype cyp 2d polymorphism breast effect concentration activity cyp 2c treatment urine neutropenia cyp 2d genotype sample level tramadol breast cancer patients variant lithium heparinized plasma phenotype group disease cyp 2d polymorphisms metabolism analysis metabolite cytochrome method cyp 3a tamoxifen therapy tamoxifen treatment frequency inhibitor breast cancer imi dose requirement cyp 2c allele tumor therapy imi dose population cyp 2d inhibitors difference adjuvant requirement outcome metabolizer cyp 2d phenotype cyp 3a allele table imipramine result association netherland promoter score van der bol lectin breast cancer res haplotype dextromethorphan mbl levels status irinotecan state collection pharmacol carrier impact cyp 2d medication genotyping mannose-binding lectin o-demethylation value survival incidence